炎症性肠病实验室诊断专家共识(2026)
近年来我国炎症性肠病发病率显著上升,结肠镜侵入性限制人群筛查应用,常规实验室指标敏感性特异性不足。本共识整合血液与粪便实验室指标,建立覆盖初筛、鉴别诊断、活动度监测及疗效评估的分层应用路径,规范粪钙卫蛋白、ASCA/pANCA抗体谱、CRP/ESR及NLR等指标使用场景。
要点
- 构建多指标联合评估体系,涵盖炎症活动、营养代谢、凝血功能及感染风险维度。
- 规范FC、ASCA/pANCA抗体谱、CRP/ESR及NLR等指标的分层临床应用场景。
- 梳理16S扩增子测序、宏基因组测序及miRNA检测等前沿技术的临床潜力。
核心结论
- 本共识旨在优化IBD非侵入性检测策略,减少误诊误治,为分级诊疗和精准防治提供规范化依据。
研究设计与样本
- 本共识为专家共识,整合血液与粪便相关实验室指标,制定覆盖初筛、鉴别诊断、活动度监测及疗效评估的分层应用路径。
主要发现
- 我国IBD发病率呈显著上升趋势,结肠镜侵入性限制其在人群筛查和长期随访中的广泛应用。
- 常规实验室指标在敏感性和特异性方面仍存在不足,单一检测难以全面评估IBD复杂的病理生理过程。
- 16S扩增子测序、宏基因组测序及miRNA检测在解析菌群结构、识别隐匿性病原体及评估宿主调控方面具有重要前景。
关键数值与推荐
- 规范了粪钙卫蛋白(FC)、抗酿酒酵母抗体(ASCA)/核周型抗中性粒细胞胞浆抗体(pANCA)抗体谱、C反应蛋白(CRP)/红细胞沉降率(ESR)及中性粒细胞-淋巴细胞比值(NLR)等指标在临床实践中的使用场景。
临床怎么用
- 采用多指标联合评估体系,从炎症活动、营养代谢、凝血功能及感染风险等多维度进行综合判断。
- 按初筛、鉴别诊断、活动度监测及疗效评估的分层路径应用实验室指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In recent years, the incidence of inflammatory bowel disease (IBD) in China has shown a significant upward trend. The invasive nature of colonoscopy limits its widespread application in population screening and long-term follow-up, while conventional laboratory parameters still suffer from insufficient sensitivity and specificity. A single test is inadequate for comprehensively assessing the complex pathophysiological processes of IBD. To enhance diagnostic efficacy, it is necessary to establish a multi-index combined evaluation system, integrating comprehensive assessments across dimensions such as inflammatory activity, nutritional metabolism, coagulation function, and infection risk. This consensus integrates relevant hematological and fecal laboratory markers, establishes a stratified application pathway covering initial screening, differential diagnosis, activity monitoring, and efficacy evaluation, and standardizes the clinical application scenarios of indicators such as fecal calprotectin (FC), the anti-Saccharomyces cerevisiae antibody (ASCA)/perinuclear anti-neutrophil cytoplasmic antibody (pANCA) panel, CRP (C-reactive protein)/ESR (erythrocyte sedimentation rate), and NLR (neutrophil-to-lymphocyte ratio). Furthermore, this consensus systematically reviews the clinical potential of cutting-edge technologies, including 16S amplicon sequencing, metagenomic sequencing, and microRNA detection, highlighting their significant prospects in analyzing microbial community structure, identifying occult pathogens, and assessing host regulation. This consensus aims to optimize non-invasive testing strategies for IBD, reduce misdiagnosis and improper treatment, and provide a standardized framework for tiered diagnosis and treatment as well as precision prevention and management. 近年来,我国炎症性肠病(IBD)的发病率呈显著上升趋势。结肠镜的侵入性特点限制了其在人群筛查和长期随访中的广泛应用,而常规实验室指标在敏感性和特异性方面仍存在不足,单一检测难以全面评估IBD复杂的病理生理过程。为提升诊断效能,需构建多指标联合评估体系,从炎症活动、营养代谢、凝血功能及感染风险等多维度进行综合判断。本共识整合血液与粪便相关实验室指标,制定了覆盖初筛、鉴别诊断、活动度监测及疗效评估的分层应用路径,规范了粪钙卫蛋白(FC)、核周型抗中性粒细胞胞浆抗体(pANCA)/抗酿酒酵母抗体(ASCA)抗体谱、C反应蛋白(CRP)/红细胞沉降率(ESR)及中性粒细胞-淋巴细胞比值(NLR)等指标在临床实践中的使用场景。同时,共识对16S扩增子测序、宏基因组测序及微小RNA(miRNA)检测等前沿技术的临床潜力进行了系统梳理,指出其在解析菌群结构、识别隐匿性病原体及评估宿主调控方面具有重要前景。本共识旨在优化IBD非侵入性检测策略,减少误诊误治,为分级诊疗和精准防治提供规范化依据。.
引用
- [Expert consensus on laboratory diagnosis of inflammatory bowel disease (2026)]. Zhonghua Yu Fang Yi Xue Za Zhi. 2026. PMID: 42161874. doi:10.3760/cma.j.cn112150-20260413-00324
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。